Merck - Racing Against the Clock

An In-Depth Analysis

In the world of global pharmaceuticals, few companies cast as large a shadow as Merck & Co. (MRK). Yet the company’s present situation is defined not by its past, but by a frantic race against the future. The central drama of Merck today is one of duality. The company is fuelled by one of the most successful drugs in history, the cancer immunotherapy Keytruda, which has reshaped oncology and generated staggering revenues. This success, however, has forged the shackles of its greatest challenge: an impending patent cliff in 2028 that threatens to erase a colossal portion of its income stream.

The company’s most recent financial results, from the third quarter of 2025, encapsulate this tension. On one hand, Keytruda’s sales continue their relentless march upwards, a testament to its enduring clinical value. On the other, cracks are appearing elsewhere in the portfolio, most notably a sharp and worrying decline in sales for its HPV vaccine, Gardasil, driven by troubles in the Chinese market. This is the narrative for any investor considering Merck. It is not a static, blue-chip behemoth to be bought and forgotten. It is a company in motion, deploying immense financial resources to build a new future before the foundations of its empire begin to crumble.

The House That Keytruda Built

To understand the scale of the challenge facing Merck, one must first appreciate the sheer magnitude of what it stands to lose. Keytruda, known scientifically as pembrolizumab, is not merely a successful product; it is a pharmaceutical phenomenon that has fundamentally altered the company’s financial DNA. It stands as the world’s best-selling drug, a title that barely does justice to its commercial dominance. In 2024 alone, Keytruda generated nearly $29.5 billion in revenue, a figure that accounted for almost half of Merck’s total sales for the year. This is not just a leading product; it is the financial engine of the entire enterprise, the source of the capital that funds its research, its acquisitions, and its generous dividend.

The third quarter of 2025 saw this trend continue, with Keytruda sales growing a further 10% YoY to reach $8.1 billion. This sustained growth, years after its initial launch, is a direct result of its scientific importance. As a PD-1 inhibitor, Keytruda was at the forefront of the immuno-oncology revolution, a new class of therapy that uses the body’s own immune system to fight cancer. Its genius lies in its broad applicability. Unlike targeted therapies that work only on specific genetic mutations, Keytruda has proven effective across an astonishingly wide array of cancers. Its approved indications span from non-small cell lung cancer and melanoma to urothelial, gastric, and cervical cancers, making it a cornerstone of modern oncology treatment protocols. This clinical utility is the base of its commercial power, creating a vast and durable revenue stream that has fuelled Merck’s prosperity for the better part of a decade.

The 2028 Patent Cliff

For every action, there is an equal and opposite reaction. In the pharmaceutical industry, the reaction to a blockbuster drug’s success is the patent cliff. This is the precipice Merck now finds itself staring into, and the drop is crazy. The primary patents protecting Keytruda’s market exclusivity are set to expire in 2028. This event will swing the doors wide open for the development and launch of biosimilars, which are near-identical, lower-cost versions of the biologic drug. The history of the pharmaceutical industry shows that the arrival of biosimilars is swift and brutal, typically eroding the sales of the original branded product at an alarming rate as healthcare systems and insurers switch to the cheaper alternatives. The loss of a drug that generates some $30 billion annually is a threat of existential proportions for any company.

Crucially, however, the market’s focus on Keytruda often obscures a more complex and perilous reality. The challenge facing Merck is not a single event in 2028 but a cascade of patent expiries across its portfolio that will exert immense pressure on its revenue base over the next four years. The company is fighting a war on multiple fronts. The cancer therapy Lenvima faces loss of exclusivity in 2025. This is followed by the blockbuster diabetes franchise, Januvia and Janumet, in 2026. In 2027, the PARP inhibitor Lynparza, a key oncology asset co-developed with AstraZeneca, loses its protection. Finally, in the same year as Keytruda, the highly successful HPV vaccine franchise, Gardasil and Gardasil 9, also faces its own patent cliff in 2028.

The company is not just preparing to replace Keytruda; it is preparing to replace a significant portion of its most profitable and established products simultaneously. This context is vital. It explains the urgency behind every decision, from research priorities to major acquisitions. Merck is not just planning for the future; it is actively attempting to rebuild its commercial foundations while the existing structure is still standing.

A Strategy for Survival and Growth

Faced with such a daunting challenge, a passive approach would be a death sentence. Merck’s management, however, is not standing idle. The company has embarked on a clear strategy designed to navigate the post-Keytruda era. This is not a single bet on one drug or technology, but a diversified and aggressive plan to defend existing territory, launch new growth drivers, and acquire external innovation. It is a strategy born of necessity, funded by Keytruda’s immense cash flows, and executed with a clear sense of the ticking clock.

The Keytruda Qlex Defence

The first part of Merck’s strategy is defensive. Recognising that it cannot compete with biosimilars on price after 2028, the company is moving to change the terms of the competition itself. The primary weapon in this fight is Keytruda Qlex, a new subcutaneous formulation of pembrolizumab that was recently approved and launched.

At first glance, this may seem like a simple product line extension. In reality, it is a profoundly strategic manoeuvre. The original Keytruda is administered as a 30-minute intravenous infusion in a clinical setting. Keytruda Qlex, by contrast, is a simple injection delivered under the skin in one or two minutes. This shift in administration represents a powerful new value proposition. For patients, it means a dramatic reduction in time spent in clinics, offering a return to normality and a significant improvement in quality of life. For healthcare systems, it means less demand on infusion centre capacity, a valuable efficiency gain.

This is the core of the defensive strategy. A patent cliff is a price-driven event. By launching Qlex, Merck is creating a product that offers a distinct advantage - convenience - that the coming wave of intravenous biosimilars will be unable to match. The goal is to convert a significant portion of the existing patient base to the subcutaneous version before 2028, creating a “sticky” ecosystem of patients and physicians who are accustomed to the new standard of care. This will not prevent the revenue decline, but it is designed to make it, as CEO Rob Davis has described, “more of a hill than a cliff”. The strategy aims to insulate a meaningful portion of the Keytruda franchise from pure price competition. Analyst forecasts support this view, projecting that Qlex could generate over $7 billion in annual sales by 2032, long after the original patent has expired, effectively extending the tail of this historic franchise.

The New Guard

If Qlex is the shield, the second part of the strategy is the sword: an aggressive push to develop and launch a new generation of blockbuster drugs to drive future growth. Merck is channelling its resources into a pipeline of assets with multi-billion dollar potential, focusing on high-growth therapeutic areas beyond its traditional strongholds.

The undisputed leader of this new guard is Winrevair. Acquired through the $11.5 billion purchase of Acceleron Pharma in 2021, Winrevair is a first-in-class, disease-modifying treatment for pulmonary arterial hypertension (PAH), a rare and severe lung disease. The drug has had a strong commercial launch, posting sales of $360 million in the third quarter of 2025. More importantly, its long-term potential is immense. Its unique mechanism of action has led analysts to project peak annual sales of over $6 billion, making it a credible pillar for the new Merck.

Complementing Winrevair is Ohtuvayre, the prize from the recent $10 billion acquisition of Verona Pharma, which closed in October 2025. Ohtuvayre is a novel inhaled therapy for chronic obstructive pulmonary disease (COPD), another vast market with significant unmet need. Its initial launch has been described by analysts as the “strongest COPD launch in history,” with projections for peak annual sales approaching $4 billion.

Within its core competency of oncology, Merck is pursuing an “inheritance” strategy with Welireg. This drug, which came from the acquisition of Peloton, is being studied in combination with Keytruda for renal cell carcinoma (RCC). The data has been highly promising, and the strategy is clear: position Welireg as the natural successor to Keytruda in the RCC market. If successful, this could not only capture Keytruda’s existing market share but expand the total revenue opportunity in this indication to over $6.3 billion annually before tapering after Keytruda’s patent expiry.

These three assets form the foundation, but the pipeline behind them is deep, with over 50 programmes in Phase 2 and more than 30 in Phase 3. Of particular note are the collaborations with Daiichi Sankyo to develop a portfolio of next-generation antibody-drug conjugates (ADCs), which represent the cutting edge of cancer therapy and hold significant future promise.

Acquiring the Future

The final part of the strategy is an explicit recognition that internal research alone may not be fast enough to fill the looming revenue gap. Merck is therefore using its financial firepower as a strategic tool, transforming itself from being solely a drug developer into a curator and acquirer of external innovation. The acquisitions of Acceleron for Winrevair and Verona for Ohtuvayre are the clearest evidence of this. These were not opportunistic purchases; they were deliberate investments to buy de-risked, late-stage, or already-commercialised assets with clear blockbuster potential.

This represents a pivot. Developing a new drug from discovery to market is a process fraught with risk, cost, and a timeline that can easily exceed a decade. With the 2028 cliff providing a fixed deadline, relying exclusively on the lottery of internal R&D is a high-risk proposition. By acquiring companies like Acceleron and Verona, Merck is trading its current cash for future certainty and speed. It is a more capital-intensive path but a faster and more reliable way to construct a new portfolio. The company’s leadership has made it clear this approach will continue, with the CEO stating that deals in the $15 billion “sweet spot” are well within the company’s comfort zone. This signals that M&A will remain a critical component of Merck’s strategy for the foreseeable future.

Navigating Troubled Waters

The path to rebuilding Merck is not, however, without significant obstacles. A credible analysis must acknowledge the serious headwinds the company is currently facing, challenges that complicate its transition and raise the stakes for its strategic execution. The most pressing of these is the decline in sales for its HPV vaccine, Gardasil.

In the third quarter of 2025, global sales of the Gardasil franchise plummeted by 24% to $1.7 billion, a decline driven almost entirely by a collapse in demand in China. The company has attributed this to a combination of factors, including weaker consumer discretionary spending in the country and elevated levels of inventory in the distribution channel. The situation became so severe that management took the drastic step of pausing all shipments of Gardasil to China from February 2025 until at least the middle of the year, a move designed to allow its local partner to clear the excess inventory. In conjunction with this, the company formally withdrew its long-term guidance for Gardasil to achieve $11 billion in annual sales, citing the uncertainty in the Chinese market.

This development is more than just a temporary earnings miss; it has profound strategic implications. The investment case for Merck in the years leading up to 2028 rested on two strong pillars: the unassailable dominance of Keytruda and the continued, robust growth of Gardasil. The crisis in China has effectively kicked out one of those pillars. This places an even greater burden on Keytruda to carry the company’s financial performance in the medium term. More importantly, it amplifies the risk and intensifies the pressure on the new launches. Winrevair and Ohtuvayre no longer just need to be successful; they now need to execute their commercial launches with near-perfection to compensate for the unexpected and significant shortfall from what was supposed to be a reliable growth driver. Any stumbles, such as Winrevair’s third-quarter sales coming in slightly below some bullish analyst expectations, will now be viewed with far greater scrutiny.

In response to these pressures and in preparation for the revenue transition, Merck has also initiated a significant financial discipline programme. The company has announced a sweeping cost-cutting campaign designed to deliver $3 billion in annual savings by the end of 2027, a plan that includes the reduction of approximately 6,000 jobs. While painful, this move is a necessary and prudent measure to streamline the organisation, improve efficiency, and prepare the company’s financial structure for the seismic shift that lies ahead. It is a clear signal that management is taking the threat of the patent cliff with the utmost seriousness.

A Decision

The crux of the investment argument for Merck is that the market is overwhelmingly pessimistic. It is pricing the company not on the potential of its strategy, but on the certainty of its greatest problem. The 2028 patent cliff is viewed as a near-inevitable catastrophe, and this sentiment is reflected in the company’s valuation metrics. With a TTM P/E ratio of ~11x, Merck trades at a significant discount to the broader pharmaceutical industry average of around 18x. This valuation gap is even more pronounced when compared to peers perceived to have clear growth narratives, such as Eli Lilly, which commands a P/E ratio north of 35x. The market has, in effect, already punished Merck for the future loss of Keytruda.

The bull case is a bet on execution. It says that the market is underestimating the efficacy of Merck’s three-pronged strategy. If management can successfully execute the transition to Keytruda Qlex to soften the revenue decline, if the newly acquired assets in Winrevair and Ohtuvayre deliver on their multi-billion dollar commercial potential, and if the internal pipeline continues to produce valuable assets like Welireg, then the current share price represents a compelling value opportunity. In this scenario, the company will have successfully navigated the cliff, and its earnings power in the 2030s will be far greater than what is currently implied by its valuation.

The bear case, on the other hand, is that the task is simply too monumental. The bears would argue that the Gardasil slump is a worrying sign of execution risk, that the new launches will inevitably face unforeseen challenges and underperform expectations, and that the hole left by nearly $30 billion in annual Keytruda sales is simply too vast to fill in such a short period. This would lead to a prolonged era of stagnant or declining earnings, justifying the current low valuation.

In this context, Merck’s dividend plays a crucial role. The company offers a dividend yield of 3.8% and has a track record of increasing its payout for 15 consecutive years. This provides a significant margin of safety for investors. It is a reward for patience while waiting for the long-term strategic narrative to unfold. For those willing to look past the ominous shadow of 2028 and focus on the pieces being assembled for the future, Merck offers a compelling, if complex, investment proposition: a chance to acquire a world-class pharmaceutical leader at a price that already assumes the worst, with a handsome dividend paid to wait for the possibility of a much brighter dawn.

Thank you for reading, let me know if you agree, and have a great day!